Chemoimmunotherapy for cancer of the head and neck.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D007573:Jaw Neoplasms / Q000628:therapy*; D007822:Laryngeal Neoplasms / Q000628:therapy*; D008048:Lip Neoplasms / Q000628:therapy; D008297:Male; D008339:Mandibular Neoplasms / Q000628:therapy; D008441:Maxillary Neoplasms / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy*; D009303:Nasopharyngeal Neoplasms / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D010307:Parotid Neoplasms / Q000628:therapy; D012468:Salivary Gland Neoplasms / Q000628:therapy; D014062:Tongue Neoplasms / Q000628:therapy; D014067:Tonsillar Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D007538:Isoniazid; D008727:Methotrexate